Skip to content
The Policy VaultThe Policy Vault

Vitrakvi (larotrectinib capsules and oral solution - Bayer) — Cigna

Solid tumors that have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation; are metastatic or where surgical resection is likely to result in severe morbidity; and have no satisfactory alternative treatments or that have progressed following treatment

Initial criteria

  • The tumor is positive for neurotrophic receptor tyrosine kinase (NTRK) gene fusion; AND
  • Patient meets ONE of the following (i or ii):
  • i. The tumor is metastatic; OR
  • ii. Surgical resection of tumor will likely result in severe morbidity.

Approval duration

1 year